We recently demonstrated that tolvaptan prevents AQP2 trafficking and function in collecting duct principal cells and reduces AQP2 excretion in two patients with SIADH paralleled by normalization of plasma sodium concentration, clearly demonstrating the central role of AQP2 blockade in the aquaretic effect of tolvaptan102. This evidence concerns the gene AQP2 and inappropriate ADH syndrome.